Data Center semiconductor sales have historically been the most resilient during recessions, adding to Nvidia Corporation's appeal as macroeconomic clouds gather. Semiconductor stocks typically fall before sales decline and recover before fundamentals improve, highlighting the logic behind "buy the dip" strategies. NVDA has one of the strongest balance sheets in the industry, adding to its appeal as a top pick for a recession scenario.
Recently, Zacks.com users have been paying close attention to Intel (INTC). This makes it worthwhile to examine what the stock has in store.
Gloo, a Boulder, Colorado-based firm that offers technology tools to Christian churches and other faith groups, said on Monday that Pat Gelsinger is joining the firm as its head of technology and executive chairman, where he will help the group develop AI tools such as virtual assistants and chatbots.
Explore the exciting world of Intel (INTC 1.15%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
In today's video, I discuss recent updates impacting Nvidia (NVDA 0.76%) and other technology companies. To learn more, check out the short video, consider subscribing, and click the special offer link below.
In the closing of the recent trading day, Intel (INTC) stood at $23.96, denoting a -0.66% change from the preceding trading day.
INTC unveils a cutting-edge AI product suite to accelerate AI deployment at enterprises' edge infrastructure.
Nvidia CEO Jensen Huang poured cold water on the idea of a consortium led by TSMC taking over its chip-manufacturing operations.
Intel Corporation NASDAQ: INTC continues to defy market headwinds, extending its stock market rally. After a 7% climb in the previous session and a cumulative increase of roughly 25% since the announcement of its new Chief Executive Officer, the semiconductor giant's shares have leveled off today.
Intel, with declining revenues, margins, and asset efficiency, faces significant challenges. Despite restructuring efforts, Intel's financial performance continues to decline, with FY24 revenues down 33% from FY21 and net income turning negative. A sum of parts of three independent units - Intel Products, Intel Foundry, and Architecture Design - points to significant shareholder value, with a potential total market cap of $393 billion.
Selling put options on Intel and CRISPR Therapeutics could yield high returns with only moderate risk, given their respective market conditions and potential upside. For Intel, selling $22 strike June 20th puts offers a 19.07% annualized yield, with a -19.8% breakeven, supported by strong fundamentals and a new CEO. For CRISPR, selling $30 strike July 18th puts offers a 13.51% annualized yield, with a -29% breakeven, backed by a promising biotech pipeline and recent drug approval.
This week, new Intel (INTC) CEO Lip-Bu Tan officially took the reins at the chip giant this week. But there is still a lot of uncertainty about what lies ahead for the chipmaker.